Zydus Lifesciences Ltd Financials
Company Logo

Zydus Lifesciences Ltd Financial Statement

Zydus Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue6005.00
Operating Expense2046.90
Net Profit2813.70
Net Profit Margin46.86
Earning Per Share27.96
EBIDTA3923.60
Effective Tax Rate20.88

Zydus Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual15,116.30
Operating Expenses Annual7,380
Operating Profit Annual8,432.50
Interest Annual463.90
Depreciation523.90
Net Profit Annual5,774.90
Tax Annual1,669.80

Zydus Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning108.10
Cash Flow from Operations3,114
Cash Flow from Investing-4,503.60
Cash Flow from Financing1,384.50
Cash Flow at the End103

Zydus Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)55.78
PBIT Margin (%)52.32
PBT Margin (%)52.21
Net PROFIT Margin (%)38.20
Return On Networth / Equity (%)31.29
Return On Networth /Employed (%)30.47
Return On Assets (%)22.16
Total Debt / Equity (X)0.39
Asset Turnover Ratio (%)0.58

Zydus Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual4,202.10
Total Current Assets Annual15,314.70
Non Current Assets Annual17,002.20
Total Shareholders Funds Annual21,190.10
Total Assets Annual32,316.90

Zydus Lifesciences Ltd Earning Calls

EPS (INR)

Expected

11.64

Reported

11.64

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Zydus Lifesciences Ltd Financials

As of Aug 6, 2025, Zydus Lifesciences Ltd has a market capitalization of 89,122.14 Cr. Value Research classifies it as a Large-Cap company.

Yes, Zydus Lifesciences Ltd is with a debt-to-equity ratio of 0.39.

In FY 2024 , Zydus Lifesciences Ltd recorded a total revenue of approximately 14,590.10 Cr marking a significant milestone in the company's financial performance.

Zydus Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.3% annually, respectively..

Zydus Lifesciences Ltd's current PE ratio is 15.43.

Zydus Lifesciences Ltd's ROCE averaged 20.5% from the FY ending March 2023 to 2025, with a median of 21.1%. It peaked at 26.8% in March 2025, reflecting strong capital efficiency over the period..

Zydus Lifesciences Ltd's latest EBIT is Rs. 7,908.60 Cr, surpassing the average EBIT of Rs. 4,949.83 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions